Compare TRTX & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRTX | CMPS |
|---|---|---|
| Founded | 2014 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 651.1M | 778.7M |
| IPO Year | N/A | 2020 |
| Metric | TRTX | CMPS |
|---|---|---|
| Price | $8.15 | $6.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $10.25 | ★ $27.14 |
| AVG Volume (30 Days) | 712.8K | ★ 4.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 11.77% | N/A |
| EPS Growth | N/A | ★ 0.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.81 | N/A |
| Revenue Next Year | $16.96 | N/A |
| P/E Ratio | $14.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.47 | $2.25 |
| 52 Week High | $9.85 | $8.90 |
| Indicator | TRTX | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 33.73 | 46.84 |
| Support Level | $7.63 | $5.95 |
| Resistance Level | $9.22 | $7.02 |
| Average True Range (ATR) | 0.20 | 0.49 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 15.65 | 17.58 |
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating-rate first mortgage loans that are secured by high-quality commercial real estate properties undergoing some form of transition and value creation.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.